Overview
This study is designed to evaluate whether the addition of nasopharyngeal lymphoid tissue ablation to full-house endoscopic sinus surgery (ESS) provides superior control of nasal mucosa inflammation compared to full-house ESS alone in patients with nasal polyps. Thirty-two adult participants will be randomly assigned to undergo either full-house ESS only or full-house ESS combined with nasopharyngeal lymphoid tissue ablation. The primary outcome will be assessed through changes in inflammatory cell profiles at 1, 3, and 6 months postoperatively. Secondary outcomes include inflammatory cytokine levels, symptom scores, endoscopic findings, polyp recurrence rates, and safety measures.
Eligibility
Inclusion Criteria:
- Aged 18-65 years
- Diagnosed with CRSwNP according to EPOS criteria
- Blood eosinophil count \> 0.3 × 10⁹/L
Exclusion Criteria:
- Pregnant or lactating women.
- Cystic fibrosis
- primary ciliary dyskinesia
- fungal ball rhinosinusitis
- systemic vasculitis or granulomatous disease
- malignancy
- immunodeficiency.
- Subjects with an upper-respiratory-tract infection within the past 4 weeks.
- Clinically significant metabolic, cardiovascular, immune, neurologic, hematologic, gastrointestinal, cerebrovascular, or respiratory disorders, or any condition that, in the investigator's opinion, could interfere with outcome assessment or compromise patient safety.
- Currently participating in another clinical trial or having participated in one within 30 days, or staff directly involved in this study.